ReviewCureus2026
Evaluating the Diagnostic Potential of Myxovirus Resistance Protein 1 (MX1) and Myxovirus Resistance Protein 2 (MX2) As Biomarkers in Idiopathic Inflammatory Myopathies.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune muscle diseases characterized by proximal muscle weakness, systemic involvement, and high morbidity. Current diagnosis relies on clinical assessment, serology, and muscle biopsy, but challenges remain due to overlapping features and cases lacking clear biomarkers. Identifying molecular markers that reflect underlying disease pathways could improve diagnostic accuracy and patient stratification. This systematic review evaluates the diagnostic potential of myxovirus resistance protein 1 (MX1) and myxovirus resistance protein 2 (MX2), two interferon-inducible genes, as biomarkers in IIM and related conditions. A comprehensive literature search of PubMed, Embase, Web of Science, Ovid, and CINAHL (2015-2025) identified studies examining MX1 and/or MX2 in muscle disease. Eligible studies assessed diagnostic accuracy, sensitivity, specificity, or clinical relevance. Data extraction and risk of bias assessment followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Joanna Briggs Institute guidelines. Evidence suggests that MX1 is consistently elevated in affected muscle tissue in IIM, particularly dermatomyositis, where it demonstrates high tissue specificity, though its expression is not exclusive to this subtype. Peripheral or blood-based MX1 measurements show promise but risk false positives and are influenced by disease activity, prior treatment, and timing of sampling. MX2 is consistently upregulated at the transcriptomic level, but protein-level data are limited, and its incremental diagnostic value over MX1 remains unclear. Sensitivity and specificity vary across studies, emphasizing the need for standardized protocols and further benchmarking against other interferon-inducible biomarkers or clinical tools. Overall, MX1 is a valuable tissue biomarker for interferon-mediated myopathies, with potential applications in diagnosis, disease activity assessment, and monitoring systemic progression. Future prospective, multicenter, and longitudinal studies are required to validate these markers, address current limitations, and determine their utility in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.